Errui Xinyue focuses on the frontier field of exosomes, operating a domestic leading platform that spans high-purity extraction, targeted enrichment, high-precision characterization and clinical application development. Based on this platform, the company offers extraction equipment, diagnostic reagents and raw materials that support both research and clinical use. Notably, it has developed a "blood-plasma neuron exosome α-synuclein" assay that enables early, non-invasive diagnosis of Parkinson’s disease. With fresh capital in hand, the company plans to establish a new R&D and manufacturing base in Hefei to complement its existing northern facility, sharply expanding its R&D and scale-up capacity. Additional priorities include upgrading its extraction/enrichment technology, accelerating clinical trials and regulatory filings for key diagnostic kits, broadening exosome applications to more disease areas, and launching health-management products based on medical-grade exosome extracts. Market education and brand building will also be intensified to enlarge its share across research and industrial channels. The newly raised Series A financing—nearly RMB 100 million—provides the runway for these initiatives; no other operating metrics were disclosed.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025